Want to see TARS full AI Analyst Report?
TARS Stock Chart & Stats
$71.45
$0.08(0.14%)
At close: 4:00 PM EDT
$71.45
$0.08(0.14%)
Day’s Range― - ―
52-Week Range$53.89 - $91.53
Previous CloseN/A
Volume446.51K
Average Volume (3M)890.25K
Market Cap
$3.48B
Enterprise Value$2.37B
Total Cash (Recent Filing)$449.69M
Total Debt (Recent Filing)$88.66M
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Nov 10, 2026EPS Estimate
-1.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding49,303,413
10 Day Avg. Volume1,116,055
30 Day Avg. Volume890,253
Financial Highlights & Ratios
PEG Ratio1.07
Price to Book (P/B)9.96
Price to Sales (P/S)7.58
P/FCF Ratio-153.35
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue3.91
Enterprise Value/Gross Profit4.31
Enterprise Value/Ebitda-67.19
Forecast
1Y Price Target
$100.88Price Target Upside41.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.11
Revenue Forecast (FY)$722.09M
Bulls Say, Bears Say
Bulls Say
XDEMVY Revenue GrowthRapid XDEMVY adoption provides a strong commercial foundation, with higher quarterly sales and raised full-year guidance indicating durable prescription demand. More than 700,000 patients treated and nearly $1 billion in cumulative sales further support the product’s market position.
High Margins And Cash GenerationThe combination of exceptionally high gross margins and positive operating and free cash flow improves the company’s ability to fund commercial expansion and development internally. If sustained, this cash generation can reduce financing dependence while supporting broader ophthalmology investment.
Expanded Retina PipelineAdding a late-stage retinal asset broadens Tarsus beyond its current commercial franchise and creates a potential second growth platform in an area lacking FDA-approved treatments. The acquisition also strengthens the company’s strategic position across ophthalmology if clinical development succeeds.
Bears Say
Continued Operating LossesDespite substantial revenue growth and strong gross margins, Tarsus has not yet reached consistent operating profitability. Continued losses indicate that selling, general, administrative, and research spending still absorbs gross profit, leaving execution and expense discipline central to the path toward durable earnings.
Costly Alkeus CommitmentThe retina expansion materially increases near- and long-term financial commitments through upfront cash, stock issuance, potential milestones, and higher research spending. These obligations can pressure liquidity, increase dilution, and reduce flexibility if development or commercialization takes longer than expected.
Retina Competitive RiskTarsus is entering Stargardt disease development behind an established Phase 3 competitor, which may complicate trial enrollment and future market positioning. Even with differentiated safety or efficacy claims, competitive progress could reduce the commercial opportunity for ALK-001.
Tarsus Pharmaceuticals News
TARS FAQ
What was Tarsus Pharmaceuticals’s price range in the past 12 months?
Tarsus Pharmaceuticals lowest stock price was $53.89 and its highest was $91.53 in the past 12 months.
What is Tarsus Pharmaceuticals’s market cap?
Tarsus Pharmaceuticals’s market cap is $3.48B.
When is Tarsus Pharmaceuticals’s upcoming earnings report date?
Tarsus Pharmaceuticals’s upcoming earnings report date is Nov 10, 2026 which is in 19 days.
How were Tarsus Pharmaceuticals’s earnings last quarter?
Tarsus Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported -$0.43 earnings per share for the quarter, missing the consensus estimate of -$0.192 by -$0.238.
Is Tarsus Pharmaceuticals overvalued?
According to Wall Street analysts Tarsus Pharmaceuticals’s price is currently Undervalued.
Does Tarsus Pharmaceuticals pay dividends?
Tarsus Pharmaceuticals does not currently pay dividends.
What is Tarsus Pharmaceuticals’s EPS estimate?
Tarsus Pharmaceuticals’s EPS estimate is -1.49.
How many shares outstanding does Tarsus Pharmaceuticals have?
Tarsus Pharmaceuticals has 49,303,413 shares outstanding.
What happened to Tarsus Pharmaceuticals’s price movement after its last earnings report?
Tarsus Pharmaceuticals reported an EPS of -$0.43 in its last earnings report, missing expectations of -$0.192. Following the earnings report the stock price went up 6.592%.
Which hedge fund is a major shareholder of Tarsus Pharmaceuticals?
Currently, no hedge funds are holding shares in TARS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tarsus Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$100.88 (41.18% Upside)
$100.88 (41.18% Upside)
Blogger Sentiment
Bullish
TARS Sentiment 83%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 604.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 5.3%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.45%
12-Months-Change
Fundamentals
Return on Equity
-13.53%
Trailing 12-Months
Asset Growth
23.46%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
TARS Company Deck
TARS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong commercial execution and robust growth driven by XDEMVY (record quarterly sales, improved full-year guidance, high margins, strong physician and patient engagement) while also announcing a transformative but costly acquisition of Alkeus to enter retina. The ALK-001 program brings promising long-term upside (solid clinical data, favorable tolerability, Phase III underway) but also increases near-term R&D and transaction-related cash commitments, extends the timeline to value realization (topline 2H 2029), and introduces competitive and payer uncertainties. Overall, operational momentum and financial flexibility support growth and strategic investment, but the company will incur higher expenses and execution risk ahead of the eventual retina readouts.View all TARS earnings summariesTARS Stock 12 Month Forecast
Average Price Target
$100.88
▲(41.18% Upside)
Technical Analysis
Viridian Therapeutics
―
Ocular Therapeutix
―
Kodiak Sciences
―
Arcutis Biotherapeutics
―
SpyGlass Pharma
―
Ownership Overview
2.75% Insiders
18.80% Mutual Funds
2.29% Other Institutional Investors
62.18% Public Companies and
Individual Investors